<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643420</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-GCF-301</org_study_id>
    <nct_id>NCT02643420</nct_id>
  </id_info>
  <brief_title>SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Breast CANCEr Patients With Docetaxel and Cyclophosphamide</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of a single dose of SPI-2012 with&#xD;
      pegfilgrastim (Neulasta [NDC 55513-190-01] manufactured by Amgen) in patients with&#xD;
      early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the&#xD;
      Duration of Severe Neutropenia (DSN) in Cycle 1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, open-label, active-controlled, multicenter study to compare&#xD;
      the efficacy and safety of SPI-2012 (a long acting myeloid growth factor) with pegfilgrastim&#xD;
      (Neulasta [NDC 55513-190-01] manufactured by Amgen) in breast cancer patients treated with TC&#xD;
      chemotherapy.&#xD;
&#xD;
      Approximately 400 patients will be enrolled and randomized in a 1:1 ratio to 2 treatment&#xD;
      arms.&#xD;
&#xD;
      Each cycle will be 21 days. Only 4 cycles will be evaluated for this study. On Day 1 of each&#xD;
      cycle, patients will receive TC chemotherapy. On Day 2 of each cycle, patients will receive&#xD;
      study drug (SPI-2012 or pegfilgrastim).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2016</start_date>
  <completion_date type="Actual">November 9, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of severe neutropenia (DSN) in Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>DSN is defined as the number of days of severe neutropenia (ANC &lt;0.5×10^9/L) from the first occurrence of an ANC below the threshold.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Time to ANC Recovery is defined as the time from chemotherapy administration until the patient's ANC increases to ≥1.5×109/L after the expected nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of ANC Nadir, defined as the patient's lowest ANC in Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Depth of ANC Nadir is defined as the lowest ANC value after administration of study drug (SPI- 2012 or pegfilgrastim) for each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Febrile Neutropenia (FN) in patients during Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Febrile neutropenia (FN) will be evaluated through daily temperature monitoring to assess for fever and frequent CBCs to assess for neutropenia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Neutropenia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SPI-2012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)&#xD;
Supplied in prefilled single-use syringes for subcutaneous injection&#xD;
Administered on Day 2 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegfilgrastim (6 mg/0.6 mL) (Neulasta® [NDC 55513-190-01] manufactured by Amgen)&#xD;
Single-dose subcutaneous injection administered on Day 2 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-2012</intervention_name>
    <description>Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle.</description>
    <arm_group_label>SPI-2012</arm_group_label>
    <other_name>Rolontis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Single-dose subcutaneous injection administered on Day 2 of each cycle.</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <other_name>Neulasta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_label>SPI-2012</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_label>SPI-2012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as&#xD;
             operable Stage I to Stage IIIA breast cancer.&#xD;
&#xD;
          -  Candidate to receive adjuvant or neo-adjuvant TC chemotherapy.&#xD;
&#xD;
          -  ECOG ≤2.&#xD;
&#xD;
          -  ANC ≥1.5×10^9/L&#xD;
&#xD;
          -  Platelet count ≥100×10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;9 g/dL&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤1.5 mg/dL&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT ≤2.5×ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.0×ULN&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix) or life-threatening disease.&#xD;
&#xD;
          -  Known sensitivity to E. coli derived products or known sensitivity to any of the&#xD;
             products to be administered during dosing&#xD;
&#xD;
          -  Concurrent adjuvant cancer therapy&#xD;
&#xD;
          -  Locally recurrent/metastatic&#xD;
&#xD;
          -  Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical&#xD;
             development within 12 months prior to the administration of study drug&#xD;
&#xD;
          -  Active infection or any serious underlying medical condition, which would impair the&#xD;
             ability of the patient to receive protocol treatment&#xD;
&#xD;
          -  Prior bone marrow or stem cell transplant&#xD;
&#xD;
          -  Used any investigational drugs, biologics, or devices within 30 days prior to study&#xD;
             treatment or plans to use any of these during the course of the study.&#xD;
&#xD;
          -  Prior radiation therapy within 30 days prior to enrollment.&#xD;
&#xD;
          -  Major surgery within 30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zane Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <disposition_first_submitted>January 23, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 23, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 5, 2020</disposition_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Long-acting Myeloid Growth Factor</keyword>
  <keyword>Early Stage Breast Cancer</keyword>
  <keyword>Docetaxel + Cyclophosphamide (TC) chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

